A Practical guide to selecting and using new Crohn's disease therapies
Elizabeth A Scoville1, Sara N Horst
1Division of Gastroenterology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Two new Crohn's disease treatments, risankizumab and upadacitinib, offer novel mechanisms of action. Subcutaneous infliximab also provides a new administration option for this chronic inflammatory condition.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Crohn's disease management has advanced with new therapeutic options.
- Understanding novel mechanisms of action is crucial for effective treatment.
Purpose of the Study:
- To review three recently approved agents for moderate to severe Crohn's disease.
- To analyze the efficacy, safety, and positioning of these new therapies.
Main Methods:
- Review of efficacy and safety data for risankizumab, upadacitinib, and subcutaneous infliximab.
- Analysis of prescribing information and clinical trial outcomes.
Main Results:
- Risankizumab (anti-interleukin-23) and upadacitinib (Janus kinase-1 inhibitor) represent novel mechanisms.
- Subcutaneous infliximab offers an alternative administration for maintenance therapy.
- Risankizumab demonstrated superiority over ustekinumab in a specific patient population.
Conclusions:
- New agents like risankizumab and upadacitinib show promise in diverse patient groups.
- Subcutaneous infliximab appears effective for maintenance therapy with good persistence.
- Further research is needed to optimize the positioning of these therapies in clinical practice.
More Related Videos
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Ulcerative Colitis in IBD
